General Atlantic reports 6.1M Seaport Therapeutics shares
Seaport Therapeutics, Inc. filed an initial Form 3 showing that General Atlantic–affiliated funds hold 6,101,582 shares of its Common Stock.
Rhea-AI Filing Summary
Seaport Therapeutics, Inc. filed an initial Form 3 showing that General Atlantic–affiliated funds hold 6,101,582 shares of its Common Stock. This amount includes 3,351,582 shares issuable upon conversion of Series B preferred stock. The holdings are reported as indirect, through multiple partnerships and investment vehicles described in the footnotes. A six-member Partnership Committee ultimately controls key general partners, and each member disclaims beneficial ownership of the shares except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock, par value $0.0001 per share ("Common Stock") | -- | -- | -- |
Footnotes (3)
- F1. Reflects 6,101,582 shares of Common Stock held by General Atlantic (SP), L.P., or General Atlantic SP, including 3,351,582 shares of Common Stock issuable upon conversion of Series B preferred stock. The limited partners that share beneficial ownership of the shares held by General Atlantic SP, or the GA Funds, are General Atlantic Partners 100, L.P., or GAP 100, General Atlantic Partners (Lux), SCSp, or GAP Lux, GAP Coinvestments III, LLC, or GAPCO III, GAP Coinvestments IV, LLC, or GAPCO IV, GAP Coinvestments V, LLC, or GAPCO V, and GAP Coinvestments CDA, L.P., or GAPCO CDA. The general partner of GAP 100 is General Atlantic GenPar, L.P., (Cont'd in FN2)
- F2. (Cont'd from FN1) or GA GenPar. General Atlantic, L.P., or GA LP, which is controlled by the Partnership Committee of GASC MGP, LLC (the "Partnership Committee"), is the managing member of GAPCO III, GAPCO IV and GAPCO V, the general partner of GAPCO CDA and GA GenPar, and the sole member of General Atlantic (SPV) GP, LLC, or GA SPV. The general partner of General Atlantic SP is GA SPV. The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, or GA GenPar Lux, and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a r.l., or GA Lux. The sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., or GenPar Bermuda. GAP (Bermuda) L.P., or GAP Bermuda, which is ultimately controlled by the Partnership Committee, is the general partner of GenPar Bermuda. (Cont'd in FN3)
- F3. (Cont'd from FN2) There are six members of the Partnership Committee. Each of the members of the Partnership Committee disclaims ownership of the shares except to the extent that he or she has a pecuniary interest therein.
Key Figures
Key Terms
beneficial ownership financial
Series B preferred stock financial
pecuniary interest financial
Partnership Committee financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does General Atlantic report owning in Seaport Therapeutics (SPTX) on this Form 3?
Are General Atlantic’s Seaport Therapeutics (SPTX) holdings direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.